Supernus' epilepsy treatment gets final FDA approval

Supernus (SUPN) receives final FDA approval for Trokendi XR, the company's once-daily treatment for epilepsy.

Supernus intends to launch the product in the next few weeks.

The FDA granted a waiver for certain requirements related to a pediatric study, and a "deferral for submission of post-marketing pediatric pharmacokinetic assessments that are due in 2019 followed by clinical assessments in 2025."

Shares +10.7%. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs